Guggenheim Has Lowered Expectations for Eli Lilly and Company (NYSE:LLY) Stock Price

Eli Lilly and Company (NYSE:LLY) had its target price dropped by Guggenheim from $1,168.00 to $1,163.00 in a research report issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s price target indicates a potential upside of 26.67% from the stock’s previous close.

Other equities research analysts have also issued research reports about the company. CICC Research lifted their price objective on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a research note on Wednesday, February 11th. Weiss Ratings restated a “buy (b)” rating on shares of Eli Lilly and Company in a research note on Friday. Morgan Stanley reiterated an “overweight” rating and set a $1,313.00 price target on shares of Eli Lilly and Company in a research report on Thursday, March 5th. Zacks Research lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Finally, Royal Bank Of Canada initiated coverage on shares of Eli Lilly and Company in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $1,250.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,221.26.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $918.12 on Monday. The company’s 50 day simple moving average is $1,001.75 and its two-hundred day simple moving average is $966.95. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The stock has a market capitalization of $867.46 billion, a PE ratio of 40.01, a P/E/G ratio of 1.03 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business’s revenue for the quarter was up 42.6% on a year-over-year basis. During the same period in the previous year, the business earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Institutional Trading of Eli Lilly and Company

A number of hedge funds have recently bought and sold shares of LLY. Maryland Capital Advisors Inc. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $25,000. Osbon Capital Management LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at about $25,000. Vermillion & White Wealth Management Group LLC increased its holdings in shares of Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after buying an additional 16 shares during the period. Evolution Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company in the second quarter worth about $29,000. Finally, Steph & Co. lifted its stake in shares of Eli Lilly and Company by 290.0% in the 3rd quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after acquiring an additional 29 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to buy Centessa Pharmaceuticals in a cash deal that pays $38/share upfront with contingent value rights that can lift the total to roughly $7.8 billion; the acquisition brings Centessa’s OX2R agonist sleep‑wake program (lead asset cleminorexton) into Lilly’s neuroscience pipeline and reduces reliance on a single franchise for future growth. Lilly to acquire Centessa press release
• Positive Sentiment: Lilly expanded its AI drug‑discovery partnership (Insilico/Insilico Medicine) in a deal worth up to ~$2.75 billion, aiming to speed molecule discovery and lower R&D costs — a strategic move that could increase pipeline throughput and long‑term earnings visibility. Lilly extends Insilico partnership (Reuters)
• Neutral Sentiment: Market reaction to the Centessa deal sent Centessa (CNTA) shares sharply higher and drove options activity; that reflects dealcertainty and investor demand for sleep‑med assets but is more about the target than an immediate P&L boost for Lilly. Options Traders Pick Up Pharma Stock After Eli Lilly Buyout
• Neutral Sentiment: Analyst/market notes were mixed: some firms keep buy ratings (Guggenheim maintained buy while trimming its target slightly) — a sign analysts view the strategic moves as supportive but remain cautious on valuation. Guggenheim price-target note (Benzinga)
• Negative Sentiment: Competitive risk: Novo Nordisk launched a multi‑month subscription for Wegovy (cash‑pay patients) to undercut prices and win share in the obesity/GLP‑1 market — increased pricing competition could pressure Lilly’s high‑margin GLP‑1 cash sales over time. Novo launches Wegovy subscription (CNBC)

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.